{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Therapy+placebo&page=2",
    "query": {
      "intervention": "Combination Therapy placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 1668,
    "total_pages": 167,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Therapy+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Therapy+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T20:20:51.355Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00361335",
      "title": "A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Golimumab",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 643,
      "start_date": "2006-09",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2014-07-29",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 20,
      "location_summary": "Peoria, Arizona • Aventura, Florida • Orlando, Florida + 17 more",
      "locations": [
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00361335"
    },
    {
      "nct_id": "NCT07619131",
      "title": "A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Laroprovstat",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin 1",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin 2",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat/Rosuvastatin 1",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Laroprovstat and Laroprovstat/Rosuvastatin 1",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat/Rosuvastatin 2",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match Laroprovstat/Rosuvastatin 2",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 600,
      "start_date": "2026-08-12",
      "completion_date": "2027-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 77,
      "location_summary": "Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 69 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07619131"
    },
    {
      "nct_id": "NCT02580305",
      "title": "SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "SUVN-502",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Donepezil",
          "type": "DRUG"
        },
        {
          "name": "Memantine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Suven Life Sciences Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 564,
      "start_date": "2015-09",
      "completion_date": "2019-11-07",
      "has_results": true,
      "last_update_posted_date": "2023-06-09",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 71,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02580305"
    },
    {
      "nct_id": "NCT06061081",
      "title": "A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "VH3739937",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2023-12-21",
      "completion_date": "2024-08-27",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 3,
      "location_summary": "Bakersfield, California • Miami, Florida • Dallas, Texas",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06061081"
    },
    {
      "nct_id": "NCT00853151",
      "title": "A Study to Test the Combination of Two Different Kinds of Medications for the Treatment of Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "LY2428757",
          "type": "DRUG"
        },
        {
          "name": "TT223",
          "type": "DRUG"
        },
        {
          "name": "Placebo for LY2428757",
          "type": "DRUG"
        },
        {
          "name": "Placebo for TT223",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 131,
      "start_date": "2009-02",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2012-04-13",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 26,
      "location_summary": "Birmingham, Alabama • Anaheim, California • Artesia, California + 23 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853151"
    },
    {
      "nct_id": "NCT02709512",
      "title": "Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Mesothelioma"
      ],
      "interventions": [
        {
          "name": "ADI-PEG 20 plus Pem Platinum",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus Pem Platinum",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Polaris Group",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 249,
      "start_date": "2017-08-01",
      "completion_date": "2022-08-15",
      "has_results": true,
      "last_update_posted_date": "2023-10-04",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02709512"
    },
    {
      "nct_id": "NCT01479465",
      "title": "Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Simtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to match SIM",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2011-12",
      "completion_date": "2015-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-17",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 56,
      "location_summary": "Huntsville, Alabama • Gilbert, Arizona • Alhambra, California + 49 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01479465"
    },
    {
      "nct_id": "NCT04313881",
      "title": "Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Magrolimab",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 539,
      "start_date": "2020-09-09",
      "completion_date": "2023-09-13",
      "has_results": true,
      "last_update_posted_date": "2024-06-27",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 47,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 32 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04313881"
    },
    {
      "nct_id": "NCT07610395",
      "title": "Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rhinovirus Infection"
      ],
      "interventions": [
        {
          "name": "VPV 1000 mg",
          "type": "DRUG"
        },
        {
          "name": "VPV 500 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Altesa Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "40 Years to 85 Years"
      },
      "enrollment_count": 180,
      "start_date": "2026-05-01",
      "completion_date": "2027-11-15",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 37,
      "location_summary": "Mobile, Alabama • Tempe, Arizona • Inglewood, California + 33 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07610395"
    },
    {
      "nct_id": "NCT01126229",
      "title": "Resveratrol for Improved Performance in the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Memory"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Low dose Resveratrol",
          "type": "DRUG"
        },
        {
          "name": "High dose Resveratrol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2009-11",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-12-11",
      "last_synced_at": "2026-09-30T20:20:51.355Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01126229"
    }
  ]
}